DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20170350

A rare case of oxcarbazepine induced Stevens Johnson Syndrome: toxic epidermal necrosis overlap

Aditi Maitra, Shashwat Bhattacharyya, Shatavisa Mukherjee, Nikhil Era

Abstract


Oxcarbazepine is a closely related analogue of carbamazepine and is useful in the monotherapy of seizures with an improved toxicity profile. Its clinical safety has been recently put under scrutiny as evidence has emerged about its adverse drug reactions and it is increasingly being reported to cause cutaneous drug eruptions. Here we report a rare case of oxcarbazepine induced Stevens Johnson - toxic epidermal necrolysis overlap.


Keywords


Adverse drug reaction, Oxcarbazepine, Stevens Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN)

Full Text:

PDF

References


Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau JC. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Archives of dermatology. 2002;138(8):1019-24.

Devi K, George S, Criton S, Suja V, Sridevi PK. Carbamazepine-The commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: A study of 7 years. Indian Journal of Dermatology, Venereology, and Leprology. 2005;71(5):325.

Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens–Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005;64(7):1134-8.

Sharma SR, Sharma N, Yeolekar ME. OXC-induced Stevens Johnson syndrome: A rare case report. Indian dermatology online journal. 2011;2(1):13.

Guleria VS, Sharda C, Rana T, Sood AK. OXC induced toxic epidermal necrolysis-a rare case report. Indian journal of pharmacology. 2015;47(4):459.

Lin LC, Lai PC, Yang SF, Yang RC. OXC-induced Stevens-Johnson syndrome: a case report. The Kaohsiung journal of medical sciences. 2009;25(2):82-6.

Keshri UP. OXC-Induced Toxic Epidermal Necrolysis: A Case Report. Journal of Drug Delivery and Therapeutics. 2012;2(4).

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clinical pharmacology and therapeutics. 1981;30(2):239.

World Health Organization. The use of the WHO-UMC system for standardized case causality assessment. Uppsala: The Uppsala Monitoring Centre; 2005.

Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. American Journal of Health-System Pharmacy. 1992;49(9):2229-32.

Shorvon S. OXC: A review. Objective assessment of neurotoxicity while shifting from carbamazepine to oxcarbazepine. Seizure. 2000;9(2):75-9.

Nielsen OA, Johannessen AC, Bardrum B. Oxcarbazepine-induced hyponatremia, a cross-sectional study. Epilepsy research. 1988;2(4):269-71.

Dam M, Ekberg R, Løyning Y, Waltimo O, Jakobsen K. A double-blind study comparing OXC and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy research. 1989;3(1):70-6.

Hu FY, Wu XT, An DM, Yan B, Stefan H, Zhou D. Pilot association study of OXC-induced mild cutaneous adverse reactions with HLA-B* 1502 allele in Chinese Han population. Seizure. 2011;20(2):160-2.